Harrow, Inc. · NASDAQ:HROW
Harrow — William Blair 46th Annual Growth Stock Conference 2026
25 slides from Harrow's conference presentation, Jun 3, 2026
Slide 1: William Blair 46th Annual Growth Stock Conference
William Blair 46th Annual Growth Stock Conference June 2026 » HARROW Your patients. Our purpose.
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio
Slide 3: Harrow. We are Ophthalmic Pharma.
Harrow. We are Ophthalmic Pharma. Founder-led Diversified Provider of Ophthalmic Disease Management Solutions in North America Key revenue drivers are best-in-class products in large Largest U.S. portfolio of prescription ophthalmic products underpenetrated markets; near-term launches support “key v
Slide 4: Harrow’s Ophthalmic Pharmaceutical Brands
Harrow’s Ophthalmic Pharmaceutical Brands BYQLOVI" — . Saaeeom YBy er ILEVRO. —|OPIDINE’ += Nevanac (nepafenac ophthalmic (racionidine hydrochloride _(nepalenacophtainc IHEEZO. ee suspension) 0.3% ophthalmic solution) suspension) 0.1% | (horace HC optic ge) 3% — Flarex’ TobraDex:ST [— (he a — tance
Slide 5: Financials & Outlook
Financials & Outlook 4éth Annual Growth Stock Conference | June 20226 HARROW
Slide 6: Key Financial Metrics & 2026 Outlook
oye hia Key Financial Metrics & 2026 Outlook Five years of consistent revenue and EBITDA expansion FIVE-YEAR TRACK RECORD Sewiee sews 441% sycace 2026 Outlook $357.5M Midpoint Q2 ‘26 Revenue Range $272.3M $159.6M $71M -$81M $130.2M $72.5M $88.6M QI: $44.2M 2021 2022 2023 2024 2025 2026E FY ‘26 Reven
Slide 7: Dry Eye Disease
Dry Eye Disease VEVYE 4éth Annual Growth Stock Conference | June 20226 HARROW
Slide 8: Dry Eye Disease Differentiation VEVYE
Dry Eye Disease Differentiation véevye (cyclosporine ophthalmic solution) 01% Dry Eye Disease Dilemma (or opportunity): First and only water-free cyclosporine for the * Large market (30+ million Americans); <10% on therapy) ~22x 7 4 : ere, f 4 signs and symptoms of DED - delivers more * Therapeutic
Slide 9: Durability of Revenue
Durability of Revenue New Rx + Refills = Compounding ~9x annual refill rate for covered patients Rx Only solution) 019% For topical application in the eye AOx ‘ea applcatin ate Pmt 2: IQVIA Xponent and intemal datasets, month of March 2026 (cyclosporine ophthalmic solution) 01% Q1 ‘26 Highlights ~25
Slide 10: Ocular Anesthesia
Ocular Anesthesia 4éth Annual Growth Stock Conference | June 20228 HARROW
Slide 11: IHEEZO Description
IHEEZO Description IHEEZO (chloroprocaine HCl ophthalmic: =) 3 . . . First-in-class: only branded ocular anesthetic approved in the U.S. in nearly 14 years Sterile, single-patient-use, . . physician-ad ered, Large TAM: >14M annual U.S. ocular procedures require surface anesthesia ophthalmic gel prep
Slide 12: IHEEZO’s Total Addressable Market
IHEEZO’s Total Addressable Market IHEEZO (chloroprocaine HCI ophthalmic, =) 3% ~1TAM+ Estimated Annual US. In-Office Procedures | Standard of Care = Ocular Surface Anesthesia ~10M+ ~1.5M+ ~1M+ ~700K Intravitreal Laser Gonioscopy Foreign Body Injections Procedures (Procedural) Removal CPT: 67028 CPT:
Slide 13: IHEEZO Key Metrics and Recent Highlights
IHEEZO Key Metrics and Recent Highlights +18% t +49% 85.5% © ~82% °° Unit demand growth! Growth in new accounts! Re-order rate’ Refina-driven volume’ QI '26 vs QI 25 QI '26 vs QI '25 Ql 26 Share of Q1 '26 units Quarterly customer unit demand? FY 2024: 128,585 units > FY 2025: 201,215 units: 56% grow
Slide 14: Ophthalmic Surgical
Ophthalmic Surgical TRIESENCE G-MELT Product Candidate 4éth Annual Growth Stock Conference | June 20226 HARROW
Slide 15: TRIESENCE Overview & Recent Highlights
TRIESENCE Overview & Recent Highlights ‘a Ayn Q1 ‘26 Highlights © Regulatory fe] g Only FDA-approved preservative-free synthetic corticosteroid for injectable ophthalmic use Zs “~ +136% f 44% \il ~28% 4% 6Qs sy, Supply Stable supply agreement with CMO; next-gen Unit Volume Growth oun frem Ocular New
Slide 16: G-MELT: IV and Opioid-Free Procedural Sedation
G-MELT: IV and Opioid-Free Procedural Sedation Fixed dose non-opioid sublingual tablet combining 3 mg midazolam + 50 mg ketamine WHAT MAKES G-MELT DIFFERENT au Zydis® Oral Dissolving Tablet (ODT) Technology Dissolves in seconds under the tongue. Exclusive license from Catalent; Regulatory Milestones
Slide 17: Anti-VEGF Biosimilars
Anti-VEGF Biosimilars 46th Annual Growth Stock Conference | June 2026 HARROW
Slide 18: Retina Expansion: Anti-VEGF Biosimilars
Retina Expansion: Anti-VEGF Biosimilars Two FDA-approved ophthalmic biosimilars acquired from Samsung Bioe pis — addressing the largest market in Ophthalmology © se PIN 25 ©Byooviz ; BY cetera ¥ Opuviz ranibizumab-nuna aflibercept-yszy First FDA-approved LUCENTIS® biosimilar FDA-approved EYLEA® bios
Slide 19: Specialty Product Focus
Specialty Product Focus VERKAZIA NATACYN IOPIDINE 4éth Annual Growth Stock Conference | June 20226 HARROW
Slide 20: The Verkazia Opportunity
— The Verkazia® Opportunity VKC is a chronic allergic eye disease — driven by immune dysregulation, across a spectrum (from highly underdiagnosed mild cases to severe and sight-threatening cases), which primarily affects children, but can reach into adulthood THE DISEASE SPECTRUM WHY IT MATTERS — TH
Slide 21: The Third Pathogen: the Natacyn Opportunity
7 The Third Pathogen: the Natacyn® Opportunity aritis is not a single infection — itis a microbiome imbalance (or dysbiosis) of the eyelid margin, driven by multiple etiologic pathogens! THE ETIOLOGIC TRIAD WHY IT MATTERS — THE CLINICAL GAP Demodex Mite: 300 - 400 micrometers (ym)? FUNGUS ON ~507 ~7
Slide 22: IOPIDINE
yO PIDINE® The only FDA-approved therapy to prevent procedural IOP spikes CLINICAL EVIDENCE Indication © Only FDA-approved product to prevent IOP spikes following in-office laser procedures ed ~91% Risk Reduction Severe IOP spikes drop from ~23% untreated to ~2% with IOPIDINE Risks if Unmanaged Eye
Slide 23: Summary
23 Summary 46th Annual Growth Stock Conference | June 2026 HARROW
Slide 24: Investment Summary
Investment Summary EARLY-STAGE GROWTH ACROSS ALL KEY REVENUE DRIVERS Why Invest In Significant untapped market opportunity across all key revenue drivers — with products still early in their Harrow Now adoption curves and positioned to drive substantial long-term revenue and high-margin growth Marke
Slide 25: Harrow – Your patients. Our purpose.
(» HARROW Your patients. Our purpose. 1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 Harrow.com Mike Biega Vice President of Investor Relations & Communications mbiega@harrowinc.com Direct: 617-913-8890 Your patients. Our purpose. 4éth Annual Growth Stock Conference | June 20228 HARROW
Harrow — William Blair 46th Annual Growth Stock Conference 2026 on 6ix